Spots Global Cancer Trial Database for Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Official Title:
Study ID: NCT00219817
Conditions
Interventions
Study Description
Brief Summary: Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Cancer Care Center, Greenbrae, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Fletcher Allen Health Care, Burlington, Vermont, United States
Cancer Outreach Associates, Abingdon, Virginia, United States
Contact Details
Name: William Polvino, MD
Affiliation: Sapphire Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
